Article

Desirable attributes of vaccines for deployment in low-resource settings

PATH, Seattle, Washington 98121. .
Journal of Pharmaceutical Sciences (Impact Factor: 2.59). 01/2013; 102(1). DOI: 10.1002/jps.23352
Source: PubMed

ABSTRACT

A number of product development partnerships are actively developing new vaccines to combat infectious diseases in developing countries. To be effective, the products under development should not only be safe, efficacious, and affordable, but they should also have additional desirable technical attributes, including enhanced stability, efficient packaging, and improved ease of delivery. New technologies are now available to achieve these attributes; however, many of the technologies have yet to be adopted by the vaccine industry. This commentary discusses the opportunities and challenges associated with advancing such attributes, especially vaccine thermostability and dose sparing strategies, and the critical issues that must be addressed to bridge the gap between technology development and product development. © 2012 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci.

1 Follower
 · 
10 Reads
  • Source
    • "However, today vaccines are mostly administered via an intramuscular (i.m.) or subcutaneous (s.c.) injection route, both of which incur difficulties such as needle phobia, low patient compliance, potential contamination by needles, and also a necessity for highly trained personnel (Levine, 2011). Moreover, injection vaccines can rarely induce effective mucosal immune responses which are a first barrier for the entry of the vast majority of human pathogens as most of them are transmitted through crossing mucus membranes (Chen and Zehrung, 2012). As a result, novel vaccines that can be vaccinated through the route other than injection are desired. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Using a procedure of emulsification-lyophilization (PEL), adjuvant lipid A-cochleates (LACs) were prepared as a carrier for model antigen bovine serum albumin (BSA). With phosphatidylserine and lipid A as emulsifiers dissolved in oil phase (O), sucrose and CaCl2 in the inner water phase (W1), and BSA, sucrose and PEG2000 in the outer water phase (W2), the W1/O/W2 emulsions were prepared and subsequently lyophilized to form a dry product which was stable enough to be stored at room temperature. Upon rehydration of the dry products, cochleates formed with a size of 800nm and antigen association rates of 38%. After vaccination of mice through oral mucosal (o.m.) administration, LACs showed no side effects but induced potent immune responses as evidenced by high levels of IgG in the sera and IgA in the salivary, intestinal and vaginal secretions of mice. In addition, high levels of IgG2a and IFN-γ in the sera or culture supernatants of splenocytes of the immunized mice were also detected. These results revealed that LACs induced a mixed Th1/Th2 response against the loaded antigens. Thus, the LACs prepared by PEL were able to induce both systemic and mucosal immune responses and may act as a potent cold-chain-free oral mucosal vaccine adjuvant delivery system (VADS).
    Full-text · Article · Apr 2014 · International Journal of Pharmaceutics
  • Source
    • "The development of heat-stable vaccines is a major focus of research efforts. This is because setting up and maintaining cold-chains in countries with limited infrastructure and high ambient temperatures adds considerable expense to vaccination programmes[79]. Developing vaccines that can be delivered without the use of needles is also of great interest[80], because of issues related to safe needle disposal and the possibility of infection with blood borne viruses, particularly hepatitis B and HIV. Much consideration is being given to the optimal timing of vaccine delivery. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Low-income countries typically lag behind industrialised nations, where the introduction of new vaccines is commonly tailored to the pressures of the commercial market. Happily in recent years this paradigm has started to change with the introduction of a univalent meningococcal A conjugate vaccine that is specifically targeted for the prevention of epidemic meningitis in Africa. The declaration of the 2010s as a New Decade of Vaccines, together with Millennium Development Goals 4 and 5, provide a strong mandate for a new approach to the development of vaccines for low-income countries, so that there has never been a more exciting time to work in this field. This review considers the opportunities and challenges of developing these new vaccines in the context of innovations in vaccinology, the need to induce protective immunity in the populations at risk and the requirement for strong partnership between the countries that will use these vaccines and different elements of the vaccine industry.
    Full-text · Article · Jun 2013 · Seminars in Immunology
  • [Show abstract] [Hide abstract]
    ABSTRACT: Next-generation rationally-designed vaccine adjuvants represent a significant breakthrough to enable development of vaccines against challenging diseases including tuberculosis, HIV, and malaria. New vaccine candidates often require maintenance of a cold-chain process to ensure long-term stability and separate vials to enable bedside mixing of antigen and adjuvant. This presents a significant financial and technological barrier to worldwide implementation of such vaccines. Herein we describe the development and characterization of a tuberculosis vaccine comprised of both antigen and adjuvant components that are stable in a single vial at sustained elevated temperatures. Further this vaccine retains the ability to elicit both antibody and TH1 responses against the vaccine antigen and protect against experimental challenge with Mycobacterium tuberculosis. These results represent a significant breakthrough in the development of vaccine candidates that can be implemented throughout the world without being hampered by the necessity of a continuous cold chain or separate adjuvant and antigen vials.
    No preview · Article · Dec 2013 · Journal of Controlled Release
Show more